{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:29:57Z","timestamp":1781825397514,"version":"3.54.5"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/ico.0000000000000032","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T13:05:53Z","timestamp":1390395953000},"page":"405-413","source":"Crossref","is-referenced-by-count":5,"title":["Inhibition of Pathological Corneal Neovascularization by a Small Peptide Derived From Human Apolipoprotein (a) Kringle V"],"prefix":"10.1097","volume":"33","author":[{"given":"Zhongxiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-xing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":". Corneal neovascularization: an anti-VEGF therapy review.","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"R2-13-20210204","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2337\/db07-1524","article-title":". Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway.","volume":"58","author":"Zheng","year":"2009","journal-title":"Diabetes"},{"key":"R3-13-20210204","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.mvr.2012.02.006","article-title":". PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression.","volume":"84","author":"Matsui","year":"2012","journal-title":"Microvasc Res"},{"key":"R4-13-20210204","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.yexcr.2005.11.008","article-title":"VEGF function in vascular pathogenesis.","volume":"312","author":"Ng","year":"2006","journal-title":"Exp Cell Res"},{"key":"R5-13-20210204","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R6-13-20210204","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":". Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul Surf"},{"key":"R7-13-20210204","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/01.RES.0000250758.63358.91","article-title":". Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton.","volume":"99","author":"Cazes","year":"2006","journal-title":"Circ Res"},{"key":"R8-13-20210204","doi-asserted-by":"crossref","first-page":"e16712","DOI":"10.1371\/journal.pone.0016712","article-title":". Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury.","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"R9-13-20210204","doi-asserted-by":"crossref","first-page":"29000","DOI":"10.1074\/jbc.M301042200","article-title":". Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a).","volume":"278","author":"Kim","year":"2003","journal-title":"J Biol Chem"},{"key":"R10-13-20210204","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1167\/iovs.08-3163","article-title":". Inhibition of pathologic retinal neovascularization by a small peptide derived from human apolipoprotein(a).","volume":"50","author":"Zhao","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-13-20210204","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ijc.24027","article-title":". A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells.","volume":"124","author":"Yi","year":"2009","journal-title":"Int J Cancer"},{"key":"R12-13-20210204","first-page":"1982","article-title":". A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo.","volume":"16","author":"Xu","year":"2010","journal-title":"Mol Vis"},{"key":"R13-13-20210204","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2353\/ajpath.2010.100314","article-title":". Substance P modulates colitis-associated fibrosis.","volume":"177","author":"Koon","year":"2010","journal-title":"Am J Pathol"},{"key":"R14-13-20210204","doi-asserted-by":"crossref","first-page":"e22745","DOI":"10.1371\/journal.pone.0022745","article-title":". Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models.","volume":"6","author":"Kavitha","year":"2011","journal-title":"PLoS One"},{"key":"R15-13-20210204","doi-asserted-by":"crossref","first-page":"e22334","DOI":"10.1371\/journal.pone.0022334","article-title":"Tumor endothelial marker 8 amplifies canonical Wnt signaling in blood vessels.","volume":"6","author":"Verma","year":"2011","journal-title":"PLoS One"},{"key":"R16-13-20210204","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.exer.2010.03.007","article-title":"Potential anti-angiogenic role of Slit2 in corneal neovascularization.","volume":"90","author":"Han","year":"2010","journal-title":"Exp Eye Res"},{"key":"R17-13-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":". Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R18-13-20210204","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1167\/iovs.04-1330","article-title":". Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.","volume":"46","author":"Zhang","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-13-20210204","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1167\/iovs.06-0728","article-title":". New tools for the evaluation of toxic ocular surface changes in the rat.","volume":"48","author":"Pauly","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-13-20210204","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.preteyeres.2010.01.002","article-title":". Novel aspects of corneal angiogenic and lymphangiogenic privilege.","volume":"29","author":"Ellenberg","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R21-13-20210204","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","article-title":"Mediators of ocular angiogenesis.","volume":"88","author":"Qazi","year":"2009","journal-title":"J Genet"},{"key":"R22-13-20210204","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ICO.0b013e3181605ff9","article-title":". Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.","volume":"27","author":"Aydin","year":"2008","journal-title":"Cornea"},{"key":"R23-13-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/ICO.0b013e31822480f9","article-title":". Anti-VEGF therapy with bevacizumab for anterior segment eye disease.","volume":"31","author":"Hosseini","year":"2012","journal-title":"Cornea"},{"key":"R25-13-20210204","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2337\/db11-1541","article-title":". Human apolipoprotein(a) kringle V inhibits ischemia-induced retinal neovascularization via suppression of fibronectin-mediated angiogenesis.","volume":"61","author":"Lim","year":"2012","journal-title":"Diabetes"},{"key":"R26-13-20210204","doi-asserted-by":"crossref","first-page":"21808","DOI":"10.1074\/jbc.M313633200","article-title":". A truncated kringle domain of human apolipoprotein(a) inhibits the activation of extracellular signal-regulated kinase 1 and 2 through a tyrosine phosphatase-dependent pathway.","volume":"279","author":"Ahn","year":"2004","journal-title":"J Biol Chem"},{"key":"R27-13-20210204","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2174\/138161207781039715","article-title":"Developing antiangiogenic peptide drugs for angiogenesis-related diseases.","volume":"13","author":"Sulochana","year":"2007","journal-title":"Curr Pharm Des"},{"key":"R28-13-20210204","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":". Ocular drug delivery.","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"key":"R29-13-20210204","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2003.11.148","article-title":". Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases.","volume":"313","author":"Kim","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R30-13-20210204","doi-asserted-by":"crossref","first-page":"e52287","DOI":"10.1371\/journal.pone.0052287","article-title":"Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system.","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000000032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:08:05Z","timestamp":1620954485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201404000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000000032","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}